Home › All Companies › CODX › Annual Report

Co-Diagnostics, Inc. (CODX) — Annual Report

AI-Powered SEC Filing Analysis

← All CODX filings
Latest Annual Report Filed: 2026-03-31

Key Insights

  • The company experienced significant growth in product and grant revenue from 2024 to 2025, indicating strong demand for their offerings.
  • Customer and grant agency concentration risks are present, with a few key customers and agencies accounting for a large portion of revenue and accounts receivable.
  • The company made a strategic acquisition of Co-Mira Diagnostics in October 2025, which could expand their product portfolio and market reach.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-31. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Co-Diagnostics, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.